Jonathan Ryder, MD

@jonathanrydermd.bsky.social

Adult ID and Assistant Prof at UNMC | Former IUSM IM & Truman State | Abx Stewie, Infxn Prevention, Digital MedEd, Podcasts, Medical History, Reading Non-Fiction, Running/Cycling | Posts are mine

@marcbonten.bsky.social Oct 13, 2026, 8:12 AMReposted by @jonathanrydermd.bsky.social

Today, the E.mbrace study is published in #Lancet Infectious Diseases: a vaccine against infections by #Escherichia #coli failed.
Study was similar to the CAPiTA study for a pneumococcal vaccine, only not for the outcome.

Why? Read my substack: mbonten.substack.com/p/e-coli-is-...
(1/)

@gregggonsalves.bsky.social Oct 13, 2026, 6:33 PMReposted by @jonathanrydermd.bsky.social

This is really terrible news. Helen was one of the best.

Helen Branswell, whose reporting on infectious diseases and public health drew acclaim, dies at 69 www.statnews.com/2026/10/13/h... via @statnews.com

@contagionlive.bsky.social Oct 12, 2026, 1:13 PMReposted by @jonathanrydermd.bsky.social

Zachary Nelson, PharmD, MPH, BCIDP, the lead author of the WikiGuidelines UTI guideline, explains why the change makes clinical sense and whether providers will embrace the new terminology. #IDsky #Medsky

Watch the full interview: www.contagionlive.com/view/new-uti...

@germhuntermd.bsky.social Oct 12, 2026, 11:54 AMReposted by @jonathanrydermd.bsky.social

New State-of-the-Art in @cidjournal.bsky.social

Recurrent and Relapsing Catheter-Related Bloodstream Infections in Patients Requiring Long-term Vascular Access

Leonard Mermel and colleagues

academic.oup.com/cid/advance-... #IDSky

@id-journal.bsky.social Oct 10, 2026, 11:00 AMReposted by @jonathanrydermd.bsky.social

Long-term vascular access pts risk recurrent infections. Team care, targeted antimicrobials, lock therapy, and careful catheter management improve outcomes and prevention. 🏥🔬💉

@jonathanrydermd.bsky.social Oct 8, 2026, 9:19 PM

👏

@firstcallid.bsky.social Oct 8, 2026, 7:06 PMReposted by @jonathanrydermd.bsky.social

Thrilled to be presenting on the BugHub World Stage at #IDWeek2026.

I'll be sharing the story of FirstCallID, how an idea from an IDWeek discussion became a web-based infectious diseases educational resource.

Hope to see you there.

📅 Thursday, Oct 22 • 8:00 AM

#IDsky #MedEd #FOAMed

@germhuntermd.bsky.social Oct 5, 2026, 1:04 PMReposted by @jonathanrydermd.bsky.social

Amikacin Liposome Inhalation Suspension in Newly Diagnosed Mycobacterium avium Complex Lung Disease: A Phase 3b, Double-blind, Randomized Clinical Trial (ENCORE)

Adding ALIS to a multidrug regimen improved respiratory outcomes and culture conversion

academic.oup.com/ajrccm/advan... #IDSky #pulmsky

Graph showing change in respiratory symptoms over time. Comparator arm seemed to be associated with greater improvement until off of therapy (month 13) at which point the lines cross and the ALIS arm is associated with greater symptom improvement , a difference that remains at month 15

Bar graph comparing culture conversion rates between treatment arms. The ALIS arm had greater proportion of culture conversion through all time points. By month 13, the rate of culture conversion was 82.4% for ALIS (95% CI 77.2-87.6) vs 55.6% (95% CI 48.9-62.3), a treatment difference of 26.8% (95% CI 18.3-35.3%), p<0.0001

@contagionlive.bsky.social Oct 4, 2026, 6:55 PMReposted by @jonathanrydermd.bsky.social

Dr. Zachary Nelson reviews #UTI guideline updates from medical societies, which highlight evolving recommendations, including a major shift in classification. @zacrobid.bsky.social #IDsky #Medsky
www.contagionlive.com/view/recent-...

@firstcallid.bsky.social Oct 4, 2026, 6:34 PMReposted by @jonathanrydermd.bsky.social

A retiring physician doesn't just hand over charts.

They hand over years of trust, history, and responsibility.

🎙️ New episode of The Host Response: Assuming Care from a Retiring Physician: Rebuilding Trust

#IDsky #MedEd

@jonathanrydermd.bsky.social Oct 5, 2026, 3:43 AM

Really enjoy these conversations about things that are often not discussed!

@jonathanrydermd.bsky.social Oct 2, 2026, 1:41 PM

I think 2020 was supposed to be San Diego. My understanding is there are only certain cities IDWeek can go to given need for the size of the conference center & international airports, so it tends to be a rotation of the same places. Smaller conferences have a lot more flexibility on location

@germhuntermd.bsky.social Oct 2, 2026, 12:36 PMReposted by @jonathanrydermd.bsky.social

Shorter is also better in ICU patients

Timsit, Roberts, @angelahuttner.bsky.social, Daneman &c State-of-the-Art in AJRCCM @atsblueeditor.bsky.social

For most ICU patients with (suspected) infections, abx can be 🛑 at 5-7d w clinical improvement

academic.oup.com/ajrccm/advan... #IDSky #CritCareSky

Duration of antibiotic therapy in sepsis and severe infections in critically ill patients decision pathway.

Day 1 empiric therapy: sampling (culture) before therapy, clinical exams, consider alternate diagnosis;

48-72h Tailor treatment and switch to targeted therapy where possible, PK optimization, source control

Indications for extended courses: endocarditis (4-6 weeks), brain abscess (6-12 weeks), spondylodiscitis (6-12w), prosthetic joint infection (6-12 w), incomplete removal abscess, empyema, retained prosthesis: individualized

Day 5-7:

if Patients NOT responding or positive cultures: reassess treatment, individualize according to source control, immune status, high risk microbiology (S aureus, candida), possible suboptimal therapy (MDR), intravascular devices, ? role of serial PCT for stopping early questioned

if Clinical improvement: STOP antibiotics

@jonathanrydermd.bsky.social Oct 2, 2026, 12:38 AM

Anybody else captivated by the Dungeon Crawler Carl series? New genre of Lit RPG is a lot of fun. I'm on book 3, listening via Audiobook which adds a lot I think. Where are my #IDSky Crawlers?!

www.theatlantic.com/culture/2026...

@jonathanrydermd.bsky.social Oct 2, 2026, 12:21 AM

I want San Diego badly!

@drboulware.bsky.social Oct 1, 2026, 7:22 PMReposted by @jonathanrydermd.bsky.social

NIH Funding rate of Early Stage Investigators (ESI). 2025 was a major drop. 2026 will be worse.

@jonathanrydermd.bsky.social Oct 2, 2026, 12:18 AM

Encourage you to listen to (or read as I did) this interview with a legend in ID talk about how to use the new SAB guidelines and what is coming next potentially. Coming off service this last week, will add it was interesting thinking about SAB in this new paradigm. More eligible for 2 weeks

@josephmarcusid.medsky.social Oct 1, 2026, 4:16 PMReposted by @jonathanrydermd.bsky.social

My second #ELSO2026 and exciting to see all of the collaborators/thought leaders moving the field forward.

Talking with clinicians at different centers, with the lack of evidence, practice patterns are drastically different and there is a need for #IDSky research in these critically ill patients.

@jonathanrydermd.bsky.social Sep 30, 2026, 3:31 AM

Can't say I used it/needed it much, but definitely like having options available in MDR infections and now we have one less :/

@josemolinagb.bsky.social Sep 29, 2026, 11:15 PMReposted by @jonathanrydermd.bsky.social

Bad news for patients with MDR infections…

Merck has announced that imipenem/relebactam supply will be discontinued in US by the end of September.

Guess this will extend to Europe soon?

We definitely need new payment models for antibiotics 🙁

www.cidrap.umn.edu/antimicrobia... #IDsky #AMSsky #AMR

Source: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Imipenem%20Anhydrous%2C%20Cilastatin%2C%20and%20Relebactam%20Anhydrous%20Injection&st=d

Older posts